Payment overview · 2025
General Payments
$432.65
24 reported records · 12 companies
Healthcare provider profile · identity verified
Paul R. Gettinger, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BREMEN, IN · NPI 1891791810
Verified facts
What the public records show
CMS Open Payments records show Paul R. Gettinger, M.D. received $432.65 in general payments during 2025 across 24 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Farxiga, Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Auvelity by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $71.72 | 16.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.30 | 13.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.24 | 10.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.92 | 10.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.75 | 8.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.30 | 7.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.40 | 7.5% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.33 | 7.0% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.93 | 6.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.87 | 4.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.00 | 3.7% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.89 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $432.65 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $50.75 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.24 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $47.24 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $43.92 | 2 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $40.68 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.63 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.30 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.40 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $30.33 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $29.93 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 88 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 91 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
129 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 335 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 295 | 81 |
| Lisinopril | Lisinopril | 269 | 73 |
| Gabapentin | Gabapentin | 186 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 47 |
| Metformin Hcl | Metformin Hcl | 168 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 148 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 44 |
| Simvastatin | Simvastatin | 140 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 139 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 38 |
| Eliquis | Apixaban | 129 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 129 | 36 |
| Famotidine | Famotidine | 122 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 23 |
| Furosemide | Furosemide | 113 | 43 |
| Losartan Potassium | Losartan Potassium | 112 | 29 |
| Valsartan | Valsartan | 111 | 32 |
| Finasteride | Finasteride | 110 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | 35 |
| Cefdinir | Cefdinir | 99 | 79 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 97 | 65 |
| Chlorthalidone | Chlorthalidone | 95 | 26 |
| Ozempic | Semaglutide | 93 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 25 |
| Jardiance | Empagliflozin | 91 | 19 |
| Farxiga | Dapagliflozin Propanediol | 88 | 15 |
| Potassium Chloride | Potassium Chloride | 86 | 29 |
| Allopurinol | Allopurinol | 80 | 25 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 80 | 59 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 19 |
| Omeprazole | Omeprazole | 77 | 20 |
| Trazodone Hcl | Trazodone Hcl | 74 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 42 |
| Buspirone Hcl | Buspirone Hcl | 66 | 14 |
| Cephalexin | Cephalexin | 66 | 37 |
| Lorazepam | Lorazepam | 66 | 14 |
| Prednisone | Prednisone | 64 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 20 |
| Tramadol Hcl | Tramadol Hcl | 56 | 20 |
| Methylprednisolone | Methylprednisolone | 55 | 38 |
| Spironolactone | Spironolactone | 55 | 17 |
| Atenolol | Atenolol | 54 | 12 |
| Alendronate Sodium | Alendronate Sodium | 52 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 19 |
| Sertraline Hcl | Sertraline Hcl | 51 | 18 |
| Carvedilol | Carvedilol | 49 | 14 |
| Lamotrigine | Lamotrigine | 48 | suppressed |
| Alprazolam | Alprazolam | 46 | 13 |
| Naproxen | Naproxen | 43 | 20 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Glimepiride | Glimepiride | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Meloxicam | Meloxicam | 38 | 18 |
| Midodrine Hcl | Midodrine Hcl | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 11 |
| Benazepril Hcl | Benazepril Hcl | 37 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 14 |
| Nystatin | Nystatin | 35 | 20 |
| Olanzapine | Olanzapine | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 11 |
| Glipizide | Glipizide | 34 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 33 | 33 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Topiramate Er | Topiramate | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 19 |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Enulose | Lactulose | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 16 |
| Temazepam | Temazepam | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 12 |
| Mupirocin | Mupirocin | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 17 |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 20 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 19 | 19 |
| Lidocaine | Lidocaine | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Fluorouracil | Fluorouracil | 14 | 12 |
| Modafinil | Modafinil | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Rufinamide | Rufinamide | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Copaxone | Glatiramer Acetate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Valtoco | Diazepam | 12 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 11 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $432.65 · 24 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AVYCAZ, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, EMBLAVEO, FARXIGA, Fluad, Flucelvax, JARDIANCE, NURTEC ODT, Ozempic, Qelbree, Rybelsus, TEFLARO, VOWST, VRAYLAR, ZAVZPRET | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error